ASCLS eNewsBytes

• Multidrug-Resistant Infections Necessitate Bacteriophage Treatment: Can We Get There in Time? November 3, 2025
  Broad-spectrum antibiotics are effective medications that target essential processes shared by various microbes, making them useful in treating microbial diseases without the need for precise diagnoses. However, their broad action can also indiscriminately eliminate both harmful and beneficial microbes, posing risks at the individual level.
• FDA Grants De Novo Approval for Home Use of Prenatal Ultrasound Platform November 3, 2025
  The Pulsenmore ES home-use prenatal ultrasound platform received De Novo approval from the FDA. It allows expectant mothers to integrate ultrasound into their prenatal care by connecting the system to a smartphone app, providing step-by-step guidance and secure transmission of video clips for remote interpretation.
• New Surgical Techniques In Breast Cancer November 3, 2025
  Recent advancements in early detection of breast cancer have led to more patients being diagnosed at treatable stages. Traditionally, surgery focused on complete tumor removal without considering cosmetic outcomes or psychological recovery.
• Enhancing ALS Diagnosis With Dual Blood Biomarkers November 3, 2025
  Diagnosing amyotrophic lateral sclerosis is challenging, particularly in differentiating it from other neurodegenerative disorders. A new study demonstrates that the combination of two blood biomarkers, serum neurofilament light chain and cardiac troponin T, significantly enhances diagnostic accuracy for amyotrophic lateral sclerosis.
• FDA Approves Blenrep for Relapsed or Refractory Multiple Myeloma November 3, 2025
  The FDA has approved Blenrep in combination with bortezomib and dexamethasone for treating adult patients with relapsed or refractory multiple myeloma.